Laura Dawson, MD

Laura A. Dawson, MD, FRCPC, discusses key takeaways from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib vs sorafenib alone in patients with hepatocellular carcinoma.

Laura A. Dawson, MD, FRCPC, discusses the NRG/RTOG 1112 study for patients with hepatocellular carcinoma which evaluated stereotactic body radiation therapy followed by sorafenib compared with sorafenib alone.

Laura A. Dawson, MD, FRCPC, discusses quality-of-life outcomes from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib versus sorafenib alone in hepatocellular carcinoma.

Laura A. Dawson, MD, FRCPC, discusses findings from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib vs sorafenib alone in hepatocellular carcinoma.

Laura Dawson, MD, FRCPC, professor, Department of Radiation Oncology, University of Toronto, discusses screening and prevention of hepatocellular carcinoma (HCC).